Chargement en cours...
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunothe...
Enregistré dans:
| Publié dans: | J Hematol Oncol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499002/ https://ncbi.nlm.nih.gov/pubmed/28679395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0506-z |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|